Evidence map›Paper›PMID 42911516›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026

Reverse vaccinology for development of vaccine against Aeromonas hydrophila infection in nile tilapia (Oreochromis niloticus).

Germana Karla de Lima Carvalho, Leticia Stheffany de Barros Cunha, Maria Luiza Evangelista de Brito, Ligia Carolina da Silva Prado, Siomar de Castro Soares, Vasco Ariston de Carvalho Azevedo, Bertram Brenig, Mateus Matiuzzi da Costa, João José de Simoni Gouveia, Gisele Veneroni Gouveia

Abstract read
PubMed Publisher
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Germana Karla de Lima CarvalhoCenter for Open Access Genomic Analysis - CALAnGO, Universidade Federal do Vale do São Francisco (Univasf), Rodovia BR-407, CEP 54.300-300, Petrolina, Pernambuco, Brazil.ORCID http://orcid.org/0009-0009-7337-6192
Leticia Stheffany de Barros CunhaCenter for Open Access Genomic Analysis - CALAnGO, Universidade Federal do Vale do São Francisco (Univasf), Rodovia BR-407, CEP 54.300-300, Petrolina, Pernambuco, Brazil.ORCID http://orcid.org/0000-0003-2501-919X
Maria Luiza Evangelista de BritoCenter for Open Access Genomic Analysis - CALAnGO, Universidade Federal do Vale do São Francisco (Univasf), Rodovia BR-407, CEP 54.300-300, Petrolina, Pernambuco, Brazil.ORCID http://orcid.org/0000-0002-9233-4758
Ligia Carolina da Silva PradoInstitute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID http://orcid.org/0000-0002-4974-8269
Siomar de Castro SoaresMicrobiology and Parasitology, Institute of Biological Sciences and Natural Sciences, Universidade Federal do Triângulo Mineiro, Uberaba, Brazil.ORCID http://orcid.org/0000-0001-7299-3724
Vasco Ariston de Carvalho AzevedoUniversidade Federal da Bahia, Salvador, BA, CEP 40170-110, Brazil.ORCID http://orcid.org/0000-0002-4775-2280
Bertram BrenigDept. of Molecular Biology of Livestock, Georg August University Göttingen, Burckhardtweg 2, Göttingen, 37077, Germany.ORCID http://orcid.org/0000-0002-7635-9656
Mateus Matiuzzi da CostaCenter for Open Access Genomic Analysis - CALAnGO, Universidade Federal do Vale do São Francisco (Univasf), Rodovia BR-407, CEP 54.300-300, Petrolina, Pernambuco, Brazil.ORCID http://orcid.org/0000-0002-9884-2112
João José de Simoni GouveiaCenter for Open Access Genomic Analysis - CALAnGO, Universidade Federal do Vale do São Francisco (Univasf), Rodovia BR-407, CEP 54.300-300, Petrolina, Pernambuco, Brazil.ORCID http://orcid.org/0000-0002-0438-094X
Gisele Veneroni GouveiaCenter for Open Access Genomic Analysis - CALAnGO, Universidade Federal do Vale do São Francisco (Univasf), Rodovia BR-407, CEP 54.300-300, Petrolina, Pernambuco, Brazil. gisele.veneroni@univasf.edu.br.ORCID http://orcid.org/0000-0003-1074-5711

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco
6 · The paper itself

Abstract

Aeromonas hydrophila is one of the main pathogens of Tilapia and has a wide range phenotype, making it difficult to prevent by a unique vaccine. And turning the majority of the treatment using antibiotics. The aim of this work was to predict vaccine candidate with potential efficacy to protect Oreochromis niloticus against Aeromonas hydrophila, applying bioinformatics tools in a reverse vaccinology approach. It was obtained 35 A. hydrophila genomes in the São Francisco Valley in Petrolina/PE/Brazil, as well as 24 A. hydrophila and 02 O. niloticus complete genomes available in Genbank. After identification of core genes of Aeromonas hydrophila and a subtractive genomics analysis between the O. niloticus genome and A. hydrophila genome, 32 of the 178 resulting proteins, were considered likely vaccine targets as they showed a high adherence probability (> 0.51) in the Vaxign tool. After BLAST analysis against the database of essential genes (DEG), 18 proteins showed defined criteria e-value (≤ 10

Indexed as

Aeromonas hydrophilaBacterial VaccinesCichlidsFish DiseasesGram-Negative Bacterial InfectionsAnimalsBacterial ProteinsBrazilComputational BiologyGenome, BacterialReverse VaccinologyVaccine DevelopmentVaccinologyBacterial ProteinsBacterial VaccinesAeromonas hydrophilaNile tilapiaReverse vaccinologyVaccines targets

Identifiers

PMID42911516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.